8.46% percent quarterly performance for Hims & Hers Health Inc (HIMS) is not indicative of the underlying story

Steve Mayer

Hims & Hers Health Inc (NYSE: HIMS) on Monday, soared 1.45% from the previous trading day, before settling in for the closing price of $53.95. Within the past 52 weeks, HIMS’s price has moved between $17.36 and $72.98.

During the last 5-year period, the sales growth of Healthcare Sector giant was 17.22%. The company achieved an average annual earnings per share of 7.56%. With a float of $202.68 million, this company’s outstanding shares have now reached $217.38 million.

Hims & Hers Health Inc (HIMS) Insider Activity

Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Hims & Hers Health Inc is 10.33%, while institutional ownership is 77.82%. The most recent insider transaction that took place on Oct 10 ’25, was worth 52,425. Before that another transaction happened on Oct 03 ’25, when Company’s Chief Financial Officer sold 11,595 for $57.72, making the entire transaction worth $669,232. This insider now owns 70,232 shares in total.

Hims & Hers Health Inc (HIMS) Earnings and Forecasts

As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 0.32 earnings per share (EPS) for the period topping the consensus outlook (set at 0.05) by 0.27. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.13 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 7.56% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.47% during the next five years compared to 17.22% growth over the previous five years of trading.

Hims & Hers Health Inc (NYSE: HIMS) Trading Performance Indicators

Hims & Hers Health Inc (HIMS) is currently performing well based on its current performance indicators. A quick ratio of 4.46 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.14. Likewise, its price to free cash flow for the trailing twelve months is 106.21.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.80, a number that is poised to hit 0.10 in the next quarter and is forecasted to reach 0.79 in one year’s time.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.